The green light from the European Medicines Agency is the first backing in the EU for the medicine, following its approval in ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

This was the ADR's second consecutive day of gains.

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

New approval brings the medicine to an earlier treatment setting and a broader patient population.